CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The Merck and Terns news release (SEC[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.
$6.7B